Immucor Inc. has agreed to pay $22 million to resolve its part in a class action alleging it conspired with a Johnson & Johnson unit to fix prices of blood-testing reagents, according to a settlement agreement granted preliminary approval Monday.
The settlement resolves claims against Immucor by hospitals and other buyers of reagents, which are used to test blood before transfusions. Immucor also agreed to cooperate in the multidistrict litigation, which will continue in Pennsylvania federal court against Johnson & Johnson subsidiary Ortho-Clinical Diagnostics Inc. over the alleged price-fixing.
“The cooperation agreement, in particular, is a valuable benefit to the settlement class because it will save time, reduce costs and provide access to information to which the plaintiffs might not otherwise have access,” the hospitals said in a Feb. 23 memorandum urging approval of the settlement.
The complete article can be accessed here.